Toronto Memory Program

Futó vizsgálatok

• Toboroz

  A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

  NCT07717411· 3. fázis· Forrás

• Toboroz

  A Post Authorization Registry Study of Participants Treated With LEQEMBI

  NCT07762092· Forrás

• Fut, nem toboroz

  A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

  NCT07169578· 3. fázis· Forrás

• Toboroz

  A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

  NCT06976216· 3. fázis· Forrás

• Toboroz

  Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

  NCT07177352· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

  NCT06653153· 3. fázis· Forrás

• Toboroz

  Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia

  NCT06584357· Forrás

• Fut, nem toboroz

  A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease

  NCT04777331· 2. fázis· Forrás

• Fut, nem toboroz

  Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease

  NCT04639050· 1/2. fázis· Forrás

• Fut, nem toboroz

  AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

  NCT04468659· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

  NCT04437511· 3. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Alzheimer-kór5 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Leállították

  Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

  NCT06304883· 3. fázis· Forrás

• Leállították

  Open-label Extension for Phase 3 Clinical Trials of Simufilam

  NCT05575076· 3. fázis· Forrás

• Lezárult

  Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens

  NCT05217927· 4. fázis· Forrás

• Leállították

  Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

  NCT05026177· 3. fázis· Forrás

• Lezárult

  A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease

  NCT05063539· 2. fázis· Forrás

• Lezárult

  An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects

  NCT04770220· 3. fázis· Forrás

• Lezárult

  A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)

  NCT04640077· 2. fázis· Forrás

• Lezárult

  Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients

  NCT04388254· 2. fázis· Forrás

• Lezárult

  OLE of Phase 2b/3 Study ANAVEX2-73-AD-004

  NCT04314934· 2/3. fázis· Forrás